These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

272 related items for PubMed ID: 11592053

  • 21. Measurement of intermolecular distances for the natural agonist Peptide docked at the cholecystokinin receptor expressed in situ using fluorescence resonance energy transfer.
    Harikumar KG, Pinon DI, Wessels WS, Dawson ES, Lybrand TP, Prendergast FG, Miller LJ.
    Mol Pharmacol; 2004 Jan; 65(1):28-35. PubMed ID: 14722234
    [Abstract] [Full Text] [Related]

  • 22. Mutations within the cholecystokinin-B/gastrin receptor ligand 'pocket' interconvert the functions of nonpeptide agonists and antagonists.
    Bläker M, Ren Y, Gordon MC, Hsu JE, Beinborn M, Kopin AS.
    Mol Pharmacol; 1998 Nov; 54(5):857-63. PubMed ID: 9804620
    [Abstract] [Full Text] [Related]

  • 23. Further evidence for a C-terminal structural motif in CCK2 receptor active peptide hormones.
    Stone SR, Giragossian C, Mierke DF, Jackson GE.
    Peptides; 2007 Nov; 28(11):2211-22. PubMed ID: 17950490
    [Abstract] [Full Text] [Related]

  • 24. Benzotriazonine as a new core structure for the design of CCK-receptor antagonists.
    Escherich A, Escrieut C, Fourmy D, Moroder L.
    J Pept Sci; 1999 Mar; 5(3):155-8. PubMed ID: 10323559
    [Abstract] [Full Text] [Related]

  • 25. Potent and subtype-selective CCK-B/gastrin receptor antagonists: 2,4-dioxo-1,5-benzodiazepines with a plane of symmetry.
    Hagishita S, Seno K, Kamata S, Haga N, Ishihara Y, Ishikawa M, Shimamura M.
    Bioorg Med Chem; 1997 Jul; 5(7):1433-46. PubMed ID: 9377103
    [Abstract] [Full Text] [Related]

  • 26. Binding sites and transduction process of the cholecystokininB receptor: involvement of highly conserved aromatic residues of the transmembrane domains evidenced by site-directed mutagenesis.
    Jagerschmidt A, Guillaume N, Roques BP, Noble F.
    Mol Pharmacol; 1998 May; 53(5):878-85. PubMed ID: 9584214
    [Abstract] [Full Text] [Related]

  • 27. Molecular modelling of CCK-A receptors.
    Van Der Bent A, Ijzerman AP, Soudijn W.
    Drug Des Discov; 1994 Nov; 12(2):129-48. PubMed ID: 9116168
    [Abstract] [Full Text] [Related]

  • 28. Evolution of gastrointestinal hormones: the cholecystokinin/gastrin family.
    Baldwin GS, Patel O, Shulkes A.
    Curr Opin Endocrinol Diabetes Obes; 2010 Feb; 17(1):77-88. PubMed ID: 19952740
    [Abstract] [Full Text] [Related]

  • 29. Molecular interactions of nonpeptide agonists and antagonists with the melanocortin-4 receptor.
    Fleck BA, Chen C, Yang W, Huntley R, Markison S, Nickolls SA, Foster AC, Hoare SR.
    Biochemistry; 2005 Nov 08; 44(44):14494-508. PubMed ID: 16262250
    [Abstract] [Full Text] [Related]

  • 30. Phylogeny of the cholecystokinin/gastrin family.
    Johnsen AH.
    Front Neuroendocrinol; 1998 Apr 08; 19(2):73-99. PubMed ID: 9578981
    [Abstract] [Full Text] [Related]

  • 31. Synthesis and biological evaluation of potent, selective, hexapeptide CCK-A agonist anorectic agents.
    Pierson ME, Comstock JM, Simmons RD, Kaiser F, Julien R, Zongrone J, Rosamond JD.
    J Med Chem; 1997 Dec 19; 40(26):4302-7. PubMed ID: 9435899
    [Abstract] [Full Text] [Related]

  • 32. A single amino acid of the cholecystokinin-B/gastrin receptor determines specificity for non-peptide antagonists.
    Beinborn M, Lee YM, McBride EW, Quinn SM, Kopin AS.
    Nature; 1993 Mar 25; 362(6418):348-50. PubMed ID: 8455720
    [Abstract] [Full Text] [Related]

  • 33. CCK-B/Gastrin receptor transmembrane domain mutations selectively alter synthetic agonist efficacy without affecting the activity of endogenous peptides.
    Bläker M, Ren Y, Seshadri L, McBride EW, Beinborn M, Kopin AS.
    Mol Pharmacol; 2000 Aug 25; 58(2):399-406. PubMed ID: 10908308
    [Abstract] [Full Text] [Related]

  • 34. Overlapping, nonidentical binding sites of different classes of nonpeptide antagonists for the human gonadotropin-releasing hormone receptor.
    Betz SF, Reinhart GJ, Lio FM, Chen C, Struthers RS.
    J Med Chem; 2006 Jan 26; 49(2):637-47. PubMed ID: 16420049
    [Abstract] [Full Text] [Related]

  • 35. The CCK(-like) receptor in the animal kingdom: functions, evolution and structures.
    Staljanssens D, Azari EK, Christiaens O, Beaufays J, Lins L, Van Camp J, Smagghe G.
    Peptides; 2011 Mar 26; 32(3):607-19. PubMed ID: 21167241
    [Abstract] [Full Text] [Related]

  • 36. Direct identification of the agonist binding site in the human brain cholecystokininB receptor.
    Anders J, Blüggel M, Meyer HE, Kühne R, ter Laak AM, Kojro E, Fahrenholz F.
    Biochemistry; 1999 May 11; 38(19):6043-55. PubMed ID: 10320330
    [Abstract] [Full Text] [Related]

  • 37. Models for the A- and B-receptor-bound conformations of CCK-8.
    Nikiforovich GV, Hruby VJ.
    Biochem Biophys Res Commun; 1993 Jul 15; 194(1):9-16. PubMed ID: 8333874
    [Abstract] [Full Text] [Related]

  • 38. 5-(Piperidin-2-yl)- and 5-(homopiperidin-2-yl)-1,4-benzodiazepines: high-affinity, basic ligands for the cholecystokinin-B receptor.
    Castro JL, Broughton HB, Russell MG, Rathbone D, Watt AP, Ball RG, Chapman KL, Patel S, Smith AJ, Marshall GR, Matassa VG.
    J Med Chem; 1997 Aug 01; 40(16):2491-501. PubMed ID: 9258356
    [Abstract] [Full Text] [Related]

  • 39. Minor structural differences in Boc-CCK-4 derivatives dictate affinity and selectivity for CCK-A and CCK-B receptors.
    Shiosaki K, Lin CW, Kopecka H, Bianchi B, Miller T, Stashko M, Witte D.
    J Med Chem; 1997 Mar 28; 40(7):1169-72. PubMed ID: 9089338
    [Abstract] [Full Text] [Related]

  • 40. Conformational and molecular modeling studies of sulfated cholecystokinin-15.
    Giragossian C, Stone S, Papini AM, Moroder L, Mierke DF.
    Biochem Biophys Res Commun; 2002 May 10; 293(3):1053-9. PubMed ID: 12051766
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.